265 related articles for article (PubMed ID: 29757324)
21. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
Taarnhøj GA; Lindberg H; Dohn LH; Omland LH; Hjøllund NH; Johansen C; Pappot H
Health Qual Life Outcomes; 2020 Jul; 18(1):225. PubMed ID: 32653005
[TBL] [Abstract][Full Text] [Related]
22. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
23. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
24. Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.
Veldhuijzen E; Walraven I; Belderbos J
JMIR Cancer; 2021 Sep; 7(3):e26574. PubMed ID: 34519658
[TBL] [Abstract][Full Text] [Related]
25. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
26. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
[TBL] [Abstract][Full Text] [Related]
27. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.
Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I
ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781
[TBL] [Abstract][Full Text] [Related]
28. Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy - A prospective pilot study.
Møller PK; Pappot H; Bernchou U; Schytte T; Mortensen ZV; Brúnni MFÁ; Dieperink KB
Tech Innov Patient Support Radiat Oncol; 2022 Mar; 21():8-15. PubMed ID: 34977367
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
30. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
[TBL] [Abstract][Full Text] [Related]
31. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients.
Gu S; Menzer C; Hay JL; Pena C; Dusza S; Lacouture ME; Markova A
Support Care Cancer; 2023 May; 31(6):337. PubMed ID: 37183206
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Sorah JD; Deal AM; Stein SI; Jonsson M; Innocenti F; Turk A; Boles JC; Irvin W; Basch EM; Sanoff HK; Wood WA
Oncologist; 2024 Jun; ():. PubMed ID: 38828490
[TBL] [Abstract][Full Text] [Related]
33. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
34. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
35. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
36. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
[TBL] [Abstract][Full Text] [Related]
37. eHealth System for Collecting and Utilizing Patient Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care) Among Cancer Patients: Mixed Methods Approach to Evaluate Feasibility and Acceptability.
Girgis A; Durcinoska I; Levesque JV; Gerges M; Sandell T; Arnold A; Delaney GP;
J Med Internet Res; 2017 Oct; 19(10):e330. PubMed ID: 28970188
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
[TBL] [Abstract][Full Text] [Related]
39. Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study.
Kang D; Kim S; Kim H; Lee M; Kong SY; Chang YJ; Sim SH; Kim YJ; Cho J
JMIR Public Health Surveill; 2023 Mar; 9():e44105. PubMed ID: 36884274
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
